Dicle University

Running trials

• Not yet recruiting

  A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk

  NCT07900633· Phase 3· Source

• Not yet recruiting

  Diet and WB-EMS Effects in Obesity

  NCT07562724· Source

• Not yet recruiting

  Turkish Chronic Total Occlusion Percutaneous Coronary Intervention Registry

  NCT07761624· Source

• Recruiting

  Entecavir Resistance-Associated Mutations in Chronic HBV Patients in Turkey (STREAM Study)

  NCT07459426· Source

• Recruiting

  Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  NCT07222566· Phase 3· Source

• Recruiting

  A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

  NCT07218380· Phase 3· Source

• Recruiting

  LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:

  NCT07186101· Phase 2· Source

• Recruiting

  This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

  NCT07028853· Phase 3· Source

• Recruiting

  A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

  NCT07062965· Phase 3· Source

• Recruiting

  This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

  NCT06758401· Phase 3· Source

• Recruiting

  A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

  NCT07060807· Phase 3· Source

• Recruiting

  A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

  NCT06997497· Phase 3· Source

• Recruiting

  Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

  NCT06731478· Phase 3· Source

• Active, not recruiting

  Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease

  NCT06760637· Phase 3· Source

• Recruiting

  Metabolic Liver Disease in Newly Diagnosed People Living With HIV (MASHIV-TR)

  NCT07737340· Source

• Recruiting

  A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

  NCT06203210· Phase 3· Source

• Active, not recruiting

  Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

  NCT05899608· Phase 3· Source

• Active, not recruiting

  A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity

  NCT06037252· Phase 2· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

  NCT05894239· Phase 3· Source

• Active, not recruiting

  A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

  NCT05702034· Phase 3· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)

  NCT05296798· Phase 3· Source

• Active, not recruiting

  Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma

  NCT05352672· Phase 3· Source

• Active, not recruiting

  A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

  NCT05288166· Phase 3· Source

• Active, not recruiting

  Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer

  NCT05169567· Phase 3· Source

• Active, not recruiting

  A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)

  NCT04819100· Phase 3· Source

• Active, not recruiting

  A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer

  NCT05091567· Phase 3· Source

• Active, not recruiting

  A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

  NCT04975308· Phase 3· Source

• Active, not recruiting

  A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)

  NCT04576455· Phase 2· Source

• Active, not recruiting

  A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

  NCT04194944· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer3 recruiting
• Metastatic breast cancer2 recruiting
• Obesity2 recruiting
• Bladder cancer1 recruiting
• Colorectal cancer1 recruiting
• Coronary artery disease1 recruiting
• Fatty liver disease (MASLD/MASH)1 recruiting
• Gastric and esophageal cancer1 recruiting
• Hepatitis B1 recruiting
• HIV1 recruiting
• Prostate cancer1 recruiting
• Type 2 diabetes1 recruiting
• Ulcerative colitis1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  NMES Plus Hypocaloric Diet: Body Composition, Cardiometabolic Markers, Irisin and Betatrophin in Women With Obesity

  NCT07675382· Source

• Recruiting

  A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy

  NCT05646862· Phase 3· Source

• Completed

  A Two-part Study to Investigate the Effects in Adults of Two Doses of Golexanolone in Patients With Primary Biliary Cholangitis (PBC) With Fatigue and Cognitive Dysfunction

  NCT07304843· Phase 1/2· Source

• Completed

  A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

  NCT05803421· Phase 3· Source

• Completed

  A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer

  NCT04619797· Phase 2/3· Source

• Completed

  A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)

  NCT04513925· Phase 3· Source

• Completed

  A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes

  NCT04255433· Phase 3· Source

• Completed

  Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma

  NCT03777657· Phase 3· Source

Trial sites

• Dicle Üniversitesi14 trials
• Dicle Üniversitesi (Site 1654)1 trial
• Dicle Üniversitesi (Site 2102)1 trial
• Dicle University1 trial
• Dicle University, Department of Nutrition and Dietetics1 trial
• Dicle University Faculty of Medicine10 trials
• Dicle University Faculty of Medicine Department of Gastroenterology1 trial
• Dicle University, Medical Faculty4 trials
• Dicle University - Medical Faculty Campus1 trial
• Dicle Üniversitesi2 trials
• Dicle University1 trial

Conditions

Diseases this institution publishes on or runs trials for.

• Hepatitis B9 works · 1 trials
• IgA nephropathy5 works · 0 trials